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ARTICLE OPEN
Integrated molecular characterisation of endometrioid ovarian
carcinoma identifies opportunities for stratification
Robert L. Hollis 1✉, Barbara Stanley1,2, John P. Thomson1, Michael Churchman1, Ian Croy1, Tzyvia Rye1, Clare Bartos1, Fiona Nussey3,
Melanie Mackean3, Alison M. Meynert4, Colin A. Semple4, Charlie Gourley1,5 and C. Simon Herrington 1,5
Endometrioid ovarian carcinoma (EnOC) is an under-investigated ovarian cancer type. Recent studies have described disease
subtypes defined by genomics and hormone receptor expression patterns; here, we determine the relationship between these
subtyping layers to define the molecular landscape of EnOC with high granularity and identify therapeutic vulnerabilities in high-
risk cases. Whole exome sequencing data were integrated with progesterone and oestrogen receptor (PR and ER) expression-
defined subtypes in 90 EnOC cases following robust pathological assessment, revealing dominant clinical and molecular features in
the resulting integrated subtypes. We demonstrate significant correlation between subtyping approaches: PR-high (PR+ /ER+ , PR
+ /ER−) cases were predominantly CTNNB1-mutant (73.2% vs 18.4%, P < 0.001), while PR-low (PR−/ER+ , PR−/ER−) cases
displayed higher TP53 mutation frequency (38.8% vs 7.3%, P= 0.001), greater genomic complexity (P= 0.007) and more frequent
copy number alterations (P= 0.001). PR-high EnOC patients experience favourable disease-specific survival independent of
clinicopathological and genomic features (HR= 0.16, 95% CI 0.04–0.71). TP53 mutation further delineates the outcome of patients
with PR-low tumours (HR= 2.56, 95% CI 1.14–5.75). A simple, routinely applicable, classification algorithm utilising
immunohistochemistry for PR and p53 recapitulated these subtypes and their survival profiles. The genomic profile of high-risk
EnOC subtypes suggests that inhibitors of the MAPK and PI3K-AKT pathways, alongside PARP inhibitors, represent promising
candidate agents for improving patient survival. Patients with PR-low TP53-mutant EnOC have the greatest unmet clinical need,
while PR-high tumours—which are typically CTNNB1-mutant and TP53 wild-type—experience excellent survival and may represent
candidates for trials investigating de-escalation of adjuvant chemotherapy to agents such as endocrine therapy.
npj Precision Oncology            (2021) 5:47 ; https://doi.org/10.1038/s41698-021-00187-y
INTRODUCTION
Ovarian cancer remains one of the most lethal malignancies in the
developed world1. Endometrioid ovarian carcinoma (EnOC) is a
unique ovarian cancer type, with distinct clinical and molecular
characteristics2,3, accounting for around 10% of ovarian carcinoma
diagnoses. A large number of EnOC patients are diagnosed at
early stage and display excellent survival following maximal
surgical cytoreduction4,5; however, a minority present with
aggressive advanced-stage disease and suffer poor clinical
outcome.
Currently, decisions regarding post-operative systemic che-
motherapy for EnOC are made within a similar framework to other
ovarian carcinoma histotypes: platinum-based chemotherapy,
often in combination with paclitaxel, is offered to most patients
with advanced stage disease and a minority of early stage cases,
depending on tumour grade and sub-stage6. Identification of
EnOC subtypes with distinct clinical behaviour has the potential to
highlight cases for which new treatment options are needed to
improve survival; molecular characterisation represents an oppor-
tunity to identify novel therapeutic vulnerabilities of high-risk and
advanced-stage cases to biologically targeted agents, while also
highlighting low-risk cases for which de-escalation of chemother-
apy may be considered.
Early molecular studies characterising the biology of EnOC have
been confounded by the inclusion of misclassified tumours now
known to represent variants of high grade serous ovarian
carcinoma (HGSOC), which is associated with markedly poorer
overall prognosis and a distinct molecular landscape compared to
EnOC4,7–9. While HGSOC can bear morphological resemblance to
high grade EnOC, immunohistochemistry (IHC) for Wilms’ tumour
1 (WT1) has emerged as a useful discriminator between true EnOC
(WT1-negative) and pseudo-endometrioid HGSOC (WT1-posi-
tive)10, and several studies have demonstrated its utility for
improving the fidelity of EnOC diagnosis11–14.
In contrast to HGSOC, genomic studies of relatively small EnOC
cohorts have identified a relatively low TP53 mutation (TP53m)
rate and a high frequency of ARID1A, CTNNB1, PTEN, PIK3CA and
KRAS mutation15–17. Early mixed-histology transcriptomic studies
of ovarian carcinoma reported that a proportion of EnOC cluster
alongside HGSOC18; while these reports likely contained occult
pseudo-endometrioid HGSOC masquerading as true EnOC, a
recent report of 36 cases identified a proportion of
contemporarily-defined EnOC that bear the high TP53m and
extensive copy number alteration (CNA) burden reminiscent of
HGSOC19. Though this study did not use routine WT1 IHC to
exclude potential HGSOC cases, these data suggest the existence
of a true EnOC subgroup with genomic features redolent of
HGSOC. Moreover, recent IHC-based studies have identified
aberrant p53 expression patterns, indicative of TP53 mutation, in
10–24% of cases20–22.
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A number of studies have endeavoured to stratify EnOC based
on the PROMISE algorithm for endometrial carcinoma classifica-
tion; however, these have failed to resolve outcome for the
majority of EnOC patients with sufficient granularity for clinical
implementation, with around 85% of cases classified within the
mismatch repair deficient (MMRd) or no specific molecular profile
(NSMP) groups which demonstrate equivalent clinical outcome,
significantly limiting the utility of PROMISE in EnOC20–22.
We recently reported two molecular studies of WT1-negative
EnOC: one using whole exome sequencing (WES) to characterise
the genomic landscape of EnOC23, and one defining molecular
subtypes of disease based on hormone receptor expression
patterns (HREP-based subtypes)24. Both studies identified patient
groups with distinct disease-specific and progression-free survival
(DSS and PFS). The WES study identified three genomic subtypes
across 112 WT1-negative EnOC cases, constructing a stepwise
classification taxonomy using TP53 and CTNNB1 mutation status,
which occur mutually exclusively. The TP53m subtype—which
accounts for around 25% of cases—was associated with markedly
inferior survival, high genomic complexity and frequent CNA
events23. Conversely, EnOC with wild-type TP53 (TP53wt) and
mutation of CTNNB1 (TP53wt/CTNNB1m group, ~40% of cases)
demonstrated low genomic complexity and few CNA events, and
these cases displayed excellent clinical outcome (10-year DSS >
90%). The remaining TP53wt/CTNNB1wt group, representing
around 30% of cases, demonstrated intermediate prognosis with
moderate genomic complexity.
The hormone receptor study performed unsupervised analysis
of progesterone receptor (PR), oestrogen receptor (ER) and
androgen receptor (AR) expression, identifying four HREP-based
subtypes driven primarily by PR and ER expression levels: PR+ /ER
+ , PR+ /ER−, PR−/ER+ and PR−/ER−24. Comparative analysis
demonstrated that the expression threshold for PR and ER
positivity lay at a histoscore of approximately 150 for both
markers. The PR+ /ER+ and PR+ /ER− (PR−high) HREP-based
subtypes demonstrated excellent prognosis, while the PR−/ER+
and PR−/ER− (PR-low) cases demonstrated poor outcome,
consistent with earlier reports of favourable prognosis in EnOC
demonstrating PR positivity25,26.
While it has become clear that EnOC comprises clinically distinct
molecular subtypes, the relationship between HREP-based and
genomic subtypes is unknown. Here, we investigate the interplay
of these two molecular subtyping layers, performing integrated
analysis to define the molecular landscape of EnOC with greater
granularity and reveal new insights into EnOC biology.
RESULTS
Cohort characteristics
A total of 90 EnOC cases (all WT1 negative) with matched WES and
HREP-based subtyping were identified (Fig. 1). Clinical character-
istics of the cohort are described in Table 1. The majority of cases
were early stage (FIGO I/II) at diagnosis (80.7%, 71 of 88 evaluable
cases). 19.0% of cases (16 of 84 evaluable cases) had macroscopic
residual disease (RD) following primary debulking surgery.
Of the total cohort, 22 cases (24.4%) were of the TP53m
genomic subtype, with 29 (32.2%) and 39 cases (47.2%) of the
TP53wt/CTNNB1wt and TP53wt/CTNNB1m subtypes, respectively.
49 cases (54.4%) were in the PR-low HREP-based subtypes (36 PR
−/ER−, 13 PR−/ER+ ) and 41 cases (45.6%) were in the PR-high
subtypes (25 PR+ /ER+ , 16 PR+ /ER−).
Genomic characteristics of hormone receptor-based subtypes
PR-high cases demonstrated lower genomic complexity, as
quantified by mutant-allele tumour heterogeneity (MATH) geno-
mic complexity score, compared to PR-low cases (median 29.7 vs
38.9, P= 0.007) (Fig. 2a), consistent with its low TP53m rate
(Supplementary Fig. 1). The median MATH scores for the PR+ /ER
+ , PR+ /ER−, PR−/ER+ and PR−/ER− subtypes were 29.7, 30.2,
40.8 and 38.8, respectively.
The HREP-based subtypes also demonstrated significantly
different CNA burden (Fig. 2b); PR-low cases displayed more
frequent CNA events compared to PR-high cases (median 37 vs 11,
P= 0.001). PR−/ER− and PR+ /ER+ cases demonstrated the
greatest and smallest CNA burden, respectively (median 41.5 vs
6 CNA events, P < 0.001). There was no significant difference in
overall CNA burden between the two PR-high (PR+ /ER+ vs PR
+ /ER−, P= 0.370) or PR-low subtypes (PR−/ER− vs PR−/ER+ ,
P= 0.101). A markedly higher frequency of copy number gain
events was noted in the PR−/ER− group specifically (median 25 vs
2, 2.5 and 4 in the PR+ /ER+ , PR+ /ER− and PR−/ER+ groups)
(Supplementary Figure 2). PR−/ER− cases demonstrated frequent
loss of LNX1 and SNORA80A, and gain of ZNF4, STK24 and
CCDC191; gain of CDK20 was common in PR-high tumours
(Supplementary Tables 1 and 2).
There was no significant difference in tumour mutational
burden (TMB) between the HREP-based subtypes (P > 0.2)
(Fig. 2c); median TMB for the PR+ /ER+ , PR+ /ER-, PR−/ER+
and PR−/ER− groups was 80, 72.5, 74 and 79, respectively. The
PR-/ER- group demonstrated the highest frequency of mutation in
Fig. 1 Case flow diagram for endometrioid ovarian carcinoma
(EnOC) cases with matched whole exome sequencing (WES) and
hormone receptor expression data. 174 EnOC cases with unsuper-
vised hormone receptor subgroup available from the previous
study24. 216 EnOC cases identified subsequent to the unsupervised
subgrouping study of hormone receptor expression patterns with
available WES23; these cases were classified by available oestrogen
and progesterone receptor (ER and PR) immunohistochemistry data,
using a histoscore threshold of ≥150. HGS, high grade serous; WT1,
Wilms’ tumour 1; QC, quality control; PR, progesterone receptor; ER,
oestrogen receptor.
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BRCA1/2, (19.4%, 7 of 36 cases). This was not statistically
significantly higher than in the other groups (5.6%, 3 of 54 cases,
P= 0.082) (Supplementary Fig. 3); however, statistical power was
limited (simulated statistical power of 0.57 to detect a difference
of 20% vs 5% in populations of n= 36 and n= 54).
14 cases (15.6%) displayed mismatch repair (MMR) protein-
encoding gene mutations (MMRm) (3 PR-/ER, 3 PR−/ER+ , 2 PR
+ /ER−, 6 PR+ /ER+ ).
Correlation of molecular subtyping layers
There was marked overlap between HREP-based and genomic
subtyping layers (P < 0.001) (Fig. 3a, Supplementary Table 3): PR-
high cases were predominantly of the TP53wt/CTNNB1m subgroup
(73.2%, 30 of 41 cases vs 18.4%, 9 of 49 PR-low cases, P < 0.001),
while the TP53m was more common in PR-low cases (38.8%, 19 of
49 cases vs 7.3%, 3 of 41 PR-high cases, P= 0.001). Specifically, the
PR+ /ER+ subtype was overwhelmingly of the TP53wt/CTNNB1m
genomic subtype (84.0%, 21 of 25) (Fig. 3b), with the lowest
TP53m rate (4.0%, 1 of 25) (Fig. 3c). Conversely, the PR-/ER- group
had the fewest TP53wt/CTNNB1m cases (16.7%, 6 of 36 cases), and
the largest proportion of TP53m (41.7%, 15 of 36 cases).
There was no association between HREP-based subtyping and
mutation status of ARID1A, PTEN or KRAS (Supplementary Table 4).
PR-high cases demonstrated a high rate of PIK3CA mutation
(63.4%, 26 of 41 vs 38.8%, 19 of 49 in PR-low, P= 0.034), but this
was not statistically significant following adjustment for multi-
plicity of testing (Bonferroni-adjusted P= 0.137) (Supplementary
Table 4).
Hormone receptor expression levels in genomic subtypes of
endometrioid ovarian carcinoma
TP53wt/CTNNB1m cases expressed high levels of PR (median PR
histoscore= 261) (Fig. 4a), while TP53m cases were predominantly
PR negative (median PR histoscore = 0, P < 0.001 vs the TP53wt/
CTNNB1m group). The TP53wt/CTNNB1wt subtype also demon-
strated significantly lower PR levels than the TP53wt/CTNNB1m
cases (median PR histoscore = 41, P < 0.001). The TP53wt/
CTNNB1m and TP53m subtypes demonstrated the highest and
lowest levels of ER expression, respectively (median ER histoscore
181 vs 6, P < 0.001) (Fig. 4b).
PR and ER histoscores showed modest but statistically
significant anti-correlation with CNA burden (rho=−0.32, P=
0.002 and −0.39, P < 0.001) and MATH genomic complexity score
(rho=−0.23, P= 0.026 and −0.27, P= 0.011).
Hormone receptor expression-based subtype is
independently associated with favourable outcome
Multivariable survival analysis of genomic and HREP-based
subtypes—accounting for stage at diagnosis, pathological grade,
patient age and presence of macroscopic RD following debulking
—identified the PR-high groups as independently associated with
prolonged survival (DSS HR for PR-high= 0.16, 95% CI 0.04–0.71;
PFS HR for PR-high= 0.29, 95% CI 0.09–0.99) (Supplementary
Tables 5 and 6).
TP53 mutation defines highest risk cases in PR-low
endometrioid ovarian carcinomas
The 10-year DSS in the PR-high and PR-low cases was 90.3% and
44.0%, respectively. Incorporation of TP53m status delineated
outcome within the PR-low group; PR-low cases with TP53m (PR-
low/TP53m) demonstrated poor outcome compared to their
TP53wt (PR-low/TP53wt) counterparts (HR for DSS= 2.56, 95% CI
1.14–5.75, P= 0.022; HR for PFS= 2.93, 95% CI 1.32–6.51, P=
0.008) and excellent outcome resolution between PR-high and PR-
low/TP53m cases (HR for DSS= 0.08, 95% CI 0.03–0.26, P < 0.0001
and HR for PFS= 0.12, 95% CI 0.04–0.31, P < 0.0001) (Fig. 5).
Leave-one-out jackknifing demonstrated negligible impact of
outlier cases within this model (PR-high vs PR-low/TP53m: median
DSS HR= 0.08, σ2= 2.6 × 10−5 median PFS HR= 0.12, σ2= 3.8 ×
10−5) (Supplementary Fig. 4). Resampling analysis to simulate non-
identical EnOC cohorts (1000 simulated cohorts of N= 90 by
resampling with replacement) demonstrated stability of the
observed survival phenotypes (PR-high vs PR-low/TP53m: median
DSS HR= 0.07, σ2= 0.003; median PFS HR= 0.11, σ2= 0.004)
Table 1. Characteristics of 90 endometrioid ovarian carcinoma
patients.
Median (N) Range (%)
Cases Total 90
Age Median years 59.5 28–88








Pathological grade3 Grade 1 53 58.9
Grade 2 13 14.4






Diagnosis period 1980s 12 13.3
1990s 37 41.1
2000 onward 41 45.6
Hormone receptor-
based subtype
PR+ /ER+ 25 27.8
PR+ /ER- 16 17.8
PR−/ER+ 13 14.4
PR−/ER− 36 40.0













No chemotherapy 20 22.5
NA 1 —
Follow-up Median years 13.1 95% CI
10.5–18.6
5-year DSS Proportion 74.3% 95% CI
65.6–84.2%
5-year PFS Proportion 69.8% 95% CI
60.7–80.2%
BMI body mass index, NA not available, RD residual disease, PRprogester-
one receptor, ER oestrogen receptor, m mutant, wt wild-type,DSS disease-
specific survival, PFS progression-free survival. 1Pelvic extension of disease.
217 stage II cases received single-agent platinum chemotherapy, 11
received platinum-taxane chemotherapy, 3 received other cytotoxic
regimes, 2 received no adjuvant chemotherapy; treatment information
for one case was unavailable. 3Using the International Federation of
Gynecology and Obstetrics (FIGO) grading system for endometrioid
ovarian carcinomas.
RL Hollis et al.
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(Supplementary Fig. 5); 99.6% and 98.9% of simulations yielded an
HR < 0.30 for DSS and PFS, respectively.
The three-tier integrated classification taxonomy significantly
delineated outcome specifically in the context of stage II disease
(DSS HR for PR-high vs PR-low/TP53m= 0.06 and PFS HR for PR-
high vs PR-low/TP53m= 0.14; P= 0.019 and P= 0.013).
Features of integrated EnOC subtypes and recapitulation with
immunohistochemistry
Compared to the PR-low/TP53wt cases, the PR-low/TP53m group
demonstrated more frequent advanced stage at diagnosis (52.6%,
10 of 19 cases vs 13.3%, 4 of 30 cases, P= 0.011) and macroscopic
RD following debulking (50.0%, 9 of 18 evaluable cases vs 14.3%, 4
of 28 evaluable cases, P= 0.022) (Supplementary Table 7).
Moreover, they demonstrated greater genomic complexity by
MATH score (median 54.7 vs 32.7, P < 0.001) and greater CNA
burden (median 98 vs 24 CNA events, P= 0.001) (Supplementary
Fig. 6a). Indeed, the clinicopathological features of PR-low/TP53wt
cases were similar to the PR-high group, showing no difference in
stage at diagnosis or RD status (P= 0.691 and P= 0.446)
(Supplementary Table 7). There was no difference in CNA burden
or MATH genomic complexity score between PR-high and PR-low/
TP53wt cases (P= 0.623 and P= 0.162) (Supplementary Fig. 6). PR-
low/TP53wt cases demonstrated significantly poorer outcome
compared to PR-high cases despite similar clinicopathological
features (DSS HR for PR-high vs PR-low/TP53wt= 0.21, 95% CI
0.07–0.67) (Fig. 5).
A simple classification algorithm utilising IHC for PR (histoscore
< 150 vs ≥150) and p53 (wild-type pattern vs aberrant expression)
recapitulated these subtypes and their survival profiles (Supple-
mentary Table 8 and Supplementary Fig. 7).
Genomic events suggest specific therapeutic vulnerabilities in
high-risk EnOC
PR-low/TP53m cases represented the highest risk EnOC patient
group (10-year DSS 31.6%); cases with PR-low/TP53wt tumours
also represented patients for which new treatment options are
needed to improve survival (10-year DSS 50.9%). 90.0% of the PR-
low/TP53wt group (27 of 30 cases) demonstrated mutations in
KRAS (12 cases), PTEN (7 cases), PIK3CA (15 cases) or BRCA1/2 (2
cases). 47.4% of the PR-low/TP53wt group demonstrated muta-
tions in KRAS (2 cases), PTEN (1 case), PIK3CA (4 cases) or BRCA1/2
(6 cases).
Fig. 2 Genomic characteristics of endometrioid ovarian carcinoma subtypes defined by hormone receptor expression patterns. aMutant-
allele tumour heterogeneity (MATH) genomic complexity score. b Total number of copy number alterations (CNAs). c Overall tumour mutation
burden (TMB). Labelled P values represent comparison of PR-high (PR+ /ER+ , PR+ /ER−) and PR-low (PR−/ER+ , PR−/ER−) cases with a
two-sided Mann Whitney-U test. For TMB analysis, statistical power to detect a difference between PR-high and PR-low was 0.78 using a two-
sided Mann Whitney-U test, assuming exponential distribution and an effect size P(X < Y) of 0.667. PR, progesterone receptor; ER, oestrogen
receptor.
Fig. 3 Relationship between endometrioid ovarian carcinoma subtypes. a Distribution of genomic subtypes across endometrioid ovarian
carcinoma groups defined by hormone receptor expression patterns. b Frequency of CTNNB1 mutation across hormone receptor-based
subtypes. c Frequency of TP53 mutation across hormone receptor-based subtypes. Labelled P values represent comparison of PR-high (PR
+ /ER+ , PR+ /ER−) (n= 41) and PR-low (PR-/ER+ , PR−/ER−) cases (n= 49) using Chi-squared test. For b and c, vertical lines represent the
95% confidence intervals for true proportion. PR, progesterone receptor; ER, oestrogen receptor; m, mutant; wt, wild-type.
RL Hollis et al.
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High-risk EnOC cases demonstrated frequent missense muta-
tion in SOX8 (26.3% in PR-low/TP53m; 10.0%, 3 of 30 in PR-low/
TP53wt), a transcription factor associated with the WNT/β-catenin
pathway.
DISCUSSION
EnOC is a relatively under-investigated type of ovarian cancer;
recently, molecular subtypes of EnOC have been described at the
genomic and protein expression level—by TP53 and CTNNB1
mutation status, and by patterns of hormone receptor expression
—and these have been associated with distinct clinicopathologi-
cal features and survival outcome23,24. Here we dissect the
relationship between genomic and HREP-based subtypes, demon-
strating marked overlap between these two subtyping layers.
We show that the TP53wt/CTNNB1m genomic subtype over-
whelmingly expresses high levels of PR and ER, while TP53m is
associated with low expression of these markers; accordingly, the
PR-high HREP-based subtypes are frequently of the TP53wt/
CTNNB1m genomic subtype, while the PR-low cases are more
frequently of the TP53m and TP53wt/CTNNB1wt genomic
subtypes.
We also demonstrate that the HREP-based subtypes display
significant differences in their global genomic landscape: PR-high
cases demonstrate low CNA burden, while CNA events are more
common in PR-low cases. In particular, the PR-/ER- subtype
displayed the highest CNA burden, with markedly more frequent
copy number gain events compared to the other subtypes. The
low rate of TP53m in PR-high cases may well underpin the reduced
CNA burden in this population.
Fig. 4 Hormone receptor expression across genomic subtypes of endometrioid ovarian carcinoma. a Histoscore for progesterone receptor
(PR) expression. Labelled P value denotes comparison of TP53m (n= 22) and TP53wt/CTNNB1m (n= 39) cases with a two-sided Mann Whitney-
U test; additionally, TP53m vs TP53wt/CTNNB1wt (n= 29) P= 0.119 and TP53wt/CTNNB1wt vs TP53wt/CTNNB1m P < 0.001. b Histoscore for
oestrogen receptor (ER) expression. Labelled P value denotes comparison of TP53m and TP53wt/CTNNB1m cases with a two-sided Mann
Whitney-U test; additionally, TP53m vs TP53wt/CTNNB1wt P= 0.164 and TP53wt/CTNNB1wt vs TP53wt/CTNNB1m P= 0.002. m, mutant; wt, wild-
type.
Fig. 5 Clinical outcome of endometrioid ovarian carcinoma cases defined by combined HREP-based subtyping and TP53mutation status.
a Disease-specific survival. Labelled hazard ratio (HR) represents comparison of PR-high with PR-low/TP53m group (P < 0.0001); additionally, HR
for PR-high vs PR-low/TP53wt= 0.21, 95% CI 0.07–0.67 and HR for PR-low/TP53m vs PR-low/TP53wt= 2.56, 95% CI 1.14–5.75. b Progression-free
survival. Labelled HR represents comparison of PR-high with PR-low/TP53m group (P < 0.0001); additionally, HR for PR-high vs PR-low/TP53wt
= 0.34, 95% CI 0.13–0.92 and HR for PR-low/TP53m vs PR-low/TP53wt= 2.93, 95% CI 1.32–6.51. PR, progesterone receptor; m, mutant; wt, wild-
type.
RL Hollis et al.
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PR-high EnOC also represents those with the lowest MATH
score, a quantitative score calculated using global mutant VAF
distributions to infer tumour genomic complexity27. The higher
MATH score in PR-low patients suggests greater intratumor
heterogeneity in these cases28, with multiple subclonal popula-
tions harbouring distinct mutational landscapes. This heterogene-
ity may well contribute to treatment failure, with greater diversity
increasing the likelihood of an EnOC cancer cell population
surviving primary chemotherapy and seeding subsequent che-
moresistant relapse. Higher genomic complexity may therefore
contribute to the poor outcome experienced by this patient
group. These data suggest that PR-low EnOC represent a subtype
reminiscent of HGSOC, demonstrating greater genomic complex-
ity, more frequent CNA events, higher rates of TP53m, and
frequent advanced stage at diagnosis with overall poor clinical
outcome3,7,8.
Multivariable analysis of molecular subtyping layers, accounting
for clinicopathological factors, demonstrated favourable outcome
in the PR-high subtypes independent of correlation with
CTNNB1m and anti-correlation with TP53m. This suggests pro-
spective classification of newly diagnosed EnOC into HREP-based
subtypes using IHC for PR and ER may represent a meaningful way
to identify EnOC patients with high- and low-risk disease. The
threshold for ER and PR positivity in this taxonomy lay at a
histoscore of approximately 150, and assessment of nuclear
marker expression by histoscore is already routinely performed as
part of the diagnostic pathology pipeline in many centres29–31.
Indeed, pathological grade demonstrated no meaningful or
significant association with outcome in this analysis (HR= 0.99
for DSS), suggesting that PR IHC—a more objective and
quantifiable marker—outperforms pathological grade with regard
to prognostication, which is assessed subjectively. This is
consistent with a recent report demonstrating the limited utility
of pathological grading in a large cohort of EnOC21.
While the PR-low groups demonstrate significantly poorer
outcome compared to their PR-high counterparts, we show that
TP53m is a useful additional discriminator within the PR-low
group. PR-low/TP53m cases harboured greatest CNA burden, were
more frequently advanced stage and incompletely surgically
resected, and demonstrated dismal prognosis. These cases
represent a patient group for which new treatment options are
most urgently needed to improve survival. By contrast, PR-low/
TP53wt cases demonstrated intermediate prognosis, despite
clinicopathological characteristics more akin to those of PR-high
cases (frequent early stage at diagnosis and complete macro-
scopic resection).
Together, these data suggest that combined use of HREP-based
and genomic data—particularly PR expression and TP53m status
—can delineate EnOC patient outcome with greater granularity.
An immunohistochemical algorithm, utilising IHC for p53 and
β-catenin—the gene products of TP53 and CTNNB1—has been
suggested as a surrogate for identifying the reported genomic
subtypes of EnOC in routine diagnostic pathology23. Given the
combined utility of HREP-based subtypes and TP53m status
described here, coupled with the reported sensitivity and
specificity issues of β-catenin IHC as a surrogate for
CTNNB1m23,32,33 and the high correlation between PR expression
and CTNNB1m, an algorithm utilising IHC for PR/ER and p53 may
provide a more practical approach by which to prospectively
classify newly diagnosed EnOC. Indeed, we demonstrate that a
simple two-marker classifier using PR and p53 IHC can identify
high- and low-risk EnOC patient groups. IHC for p53, ER and PR is
already routinely performed as part of the pathological diagnostic
pipeline across many centres, and identification of subtypes in this
way is therefore readily implementable with relatively low cost
and little change in current practice. Validation of this classifica-
tion approach in an independent cohort is required prior to its
potential implementation.
By comparison, efforts to apply the endometrial carcinoma
molecular classifier—the PROMISE algorithm—have not identified
a sizeable proportion of excellent prognosis EnOC patients20–22;
POLE-mutated tumours are reportedly associated with around
90% 10-year overall patient survival, but account for only 3.5% of
cases, limiting implementation of POLE as a prognostic marker.
Moreover, two of the four subtypes identified by this algorithm—
the MMRd and NSMP groups—account for around 85% of cases
and demonstrate equivalent clinical behaviour21, limiting the
utility of this classification system.
The identification of patients at higher risk of disease relapse is
arguably the highest priority for studies investigating patient
stratification. While identification of low-risk patients for de-
escalation of therapy may spare some patients the adverse effects
of systemic chemotherapy, identifying those who derive most
benefit from systemic cytotoxic agents and novel treatment
options represents an opportunity to rescue the greatest number
of life years. The PR-low/TP53m and PR-low/TP53wt groups
represent cases for which new treatment options are needed to
improve survival. The genomic profiles of PR-low/TP53wt cases
demonstrated frequent KRAS, PTEN and PIK3CA mutations, high-
lighting MAPK and PIK3-AKT pathway inhibitors as candidate
agents of potential therapeutic utility in this patient group.
Indeed, inhibition of the MAPK pathway has recently demon-
strated favourable efficacy in low grade serous ovarian carci-
noma34, which is known to demonstrate frequent KRAS
mutation35. By contrast, PR-low/TP53m tumours rarely demon-
strate such mutations; however, around one third (31.6%, 6 of 19)
display mutation of BRCA1/2, suggesting exploration of poly-(ADP-
ribose) polymerase (PARP) inhibitor efficacy in this population is
warranted.
PR-low/TP53m cases also demonstrated a high rate of missense
mutation in SOX8, encoding a transcription factor implicated in
the regulation of WTN/β-catenin signalling36; while the precise
signalling consequences of such mutations are not yet well
defined, these data suggest that inhibitors of the WNT pathway
may represent a candidate therapeutic strategy in these cases,
with few other recurrent targetable events identified in this
patient population. The marked clinical and molecular hetero-
geneity demonstrated by EnOC highlights the critical need for
rationally designed trials to account for molecular subtypes of
disease when investigating new agents for EnOC.
Endocrine therapy has been suggested as a potential treatment
strategy for EnOC37. In particular, de-escalation of primary
treatment from chemotherapy to endocrine therapy has been
suggested as a potential approach for patients with stage II EnOC
with zero macroscopic RD who would otherwise receive cytotoxic
chemotherapy24, which has both significant toxicities and
resource implications. By contrast, endocrine therapy is well
tolerated, does not need to be delivered at a specialist centre, and
is low in cost38. Indeed, there has been growing interest in the use
of these agents in ovarian cancer as both treatment for relapsed
HGSOC39,40 and maintenance therapy for LGSOC41, which is
typically ER-positive25. In relapsed HGSOC, high ER histoscore and
prolonged treatment-free interval have been associated with
greater efficacy of endocrine agents40. We demonstrate that
TP53wt/CTNNB1m EnOC are overwhelmingly positive for ER and
PR, suggesting this subtype of patients may represent those most
likely to benefit from such strategies. Given the high rate of early
stage disease (FIGO stage I/II) and complete surgical resection in
this subtype, efforts aimed at assessing the feasibility of adjuvant
chemotherapy de-escalation should focus on this patient popula-
tion. Endocrine agents represent a potential alternative treatment
strategy worthy of investigation in this low-risk patient group.
This study makes use of a unique, robustly defined EnOC cohort
with matched genomic and hormone reception expression data;
while this affords the opportunity to perform integrated analyses
that were not previously possible in this disease type, we
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recognise a number study limitations. To our knowledge, no other
dataset of this type is available with matched genomic
characterisation and PR/ER expression data; as such, we were
unable to utilise an independent dataset to validate our findings.
We have, however, employed leave-one-out jackknifing and
permutative resampling approaches to assess the impact of
outliers and simulate the effect size of our integrated classification
model in non-identical EnOC cohorts. We also recognise our
application of multiple independent statistical analyses, though
we have applied multiplicity correction where appropriate and
note that the survival associations we report are highly statistically
significant (P < 0.0001 in our final DSS model; PR-high vs PR-low/
TP53m).
Together, these data shed light on the overlay and interplay of
molecular subtyping layers in EnOC and highlight the distinct
clinical and molecular phenotypes displayed by these patient
groups. Patients with PR-low EnOC harbouring TP53m represent
the highest risk group, with frequent disease relapse; these
patients experience poor prognosis, in stark contrast to those with
PR-high tumours, which are typically TP53wt, frequently harbour
CTNNB1m and are associated with excellent patient survival. The
low PR and ER expression in TP53m cases suggests that they are
unlikely to benefit from endocrine therapy, while PR-high cases
may represent the best candidates for these agents.
Future work should seek to validate the clinical impact of these
groups in an independent cohort of EnOC and investigate new
treatment options for high risk patients. Rigorous contemporary
pathological review, with routine use of WT1 IHC to exclude
pseudo-endometrioid HGSOC, will be essential for robust valida-
tion. Inhibitors of the MAPK and PI3K-AKT pathways represent
promising candidates for improving outcome in PR-low/TP53wt
EnOC. By contrast, the PR-low/TP53m group demonstrates fewer
clinically actionable recurrent mutations. PARP inhibitors represent
promising agents for BRCA1/2 mutant patients within this highest
risk population; inhibitors of the WNT/β-catenin pathway repre-
sent further agents worthy of investigation in this subtype given
the high frequency of mutation in SOX8. IHC for PR and p53—both
of which are already performed within the routine diagnostic
pipeline for ovarian tumours—represents a readily implementable
approach for identifying high- and low-risk EnOC patient groups.
METHODS
Cohort identification and clinical annotation
A total of 112 EnOC cases underwent WES following pathological review as
previously described23, of which 90 cases had matching PR and ER
expression data (Fig. 1). Of 505 identified ovarian cancer cases with a
documented EnOC diagnosis, tumour material was available for 289 cases
and pathology review was performed by an expert gynecological
pathologist (CSH), which included WT1 IHC for every case. WT1 IHC was
performed with 1:1000 anti-human WT1 monoclonal mouse antibody
clone 6F-H2 on the Leica BOND III Autostainer using IHC protocol F. WT1-
positive cases, tumours of non-ovarian primary, and ovarian cancer
histotypes other than EnOC were excluded (Fig. 1). Ethical approval for the
study was obtained from NHS Lothian Research and Development
(reference 2007/W/ON/29) and Lothian NRS BioResource (reference 15/
ES/0094-SR494). All relevant ethical regulations have been complied with,
including the need for written informed consent where required.
Clinicopathological characteristics at diagnosis, treatment details and
outcome data were retrieved from the Edinburgh Ovarian Cancer
Database4. DSS and PFS were calculated from date of pathologically
confirmed diagnosis; PFS was defined as time to radiologically confirmed
recurrence or progression, or death from EnOC.
Genomic characterisation
Genomic data were available from the previous WES study of 112 EnOC
cases23. Formalin-fixed paraffin-embedded (FFPE) tumour material was
macrodissected using haematoxylin and eosin-stained slides as a guide,
marked to identify tumour areas by an expert pathologist (CSH). DNA was
extracted using the Qiagen QIAamp DNA FFPE Tissue Kit and Depar-
affinization Solution. Tumour DNA underwent WES to a mean per-sample
on-target depth of 89.5X using the Illumina TruSeq Exome Library Prep kit
on an Illumina NextSeq 550, and processed as previously described using
the bcbio-nextgen integrated bioinformatic pipeline (v1.0.9)23.
Briefly, reads were aligned to GRCh38 with BWA v0.7.17, duplicates were
marked, base quality scores were recalibrated, and variant calling was
performed using a majority vote system between three variant callers
(Mutect242, VarDict43 and Freebayes44). Variants were filtered for FFPE and
oxidation artefacts, low variant allele frequency (VAF) (<10%), low variant
coverage (<20X), and for common variants using the ExAC (ExAC.0.3.
GRCh38) and 1000 Genomes (Version phase 1 SNP and InDel) reference
datasets. Variants of known functional significance were flagged using the
ClinVar database, and remaining variants were annotated using PolyPhen
and SIFT prediction tools to filter likely non-functional variants.
TMB was calculated as the mutation count per sample, following the
above-described filtering steps. CNA events were identified using the
GeneCN pipeline in bio-DB-HTS version 2.10. Genomic complexity was
quantified by MATH score, calculated from per-sample VAF density
distribution using the inferHeterogeneity function in the maftools R
package27.
Hormone receptor expression and p53 immunohistochemistry
ER and PR expression data were available for 90 of the 112 EnOC cases
characterised by WES (Fig. 1)24. IHC for PR and ER was performed on
human tissue microarrays comprising three 0.8 mm cores per case, as
previously described24. IHC used 1:50 mouse anti-PR antibody M3569 clone
PgR-636 and 1:50 rabbit anti-ER antibody M3643 clone EP1; PR and ER IHC
was performed on the Leica BOND III Autostainer and expression was
assessed by histoscore, a quantitative nuclear expression score incorporat-
ing staining intensity and proportion of positive tumour nuclei31. HREP-
based subtype was available for 74 cases from the unsupervised subtyping
study24;16 further cases were classified based on their PR and ER histoscore
using a threshold of histoscore ≥150 for positivity, as indicated by the
unsupervised subtyping study24 (Fig. 1).
p53 IHC data were available for 87 of the 90 cases23. IHC was performed
on the Leica BOND III Autostainer using a 1:50 dilution of p53 antibody
(clone DO-7, DAKO). Wild-type pattern was defined as variable nuclear
staining intensity, while aberrant staining was defined as strong diffuse
nuclear positivity (aberrant positive) or complete absence of nuclear
staining (aberrant null).
Statistical analysis
Statistical analyses were performed using R 4.0.3. Categorical variables
were compared using Fisher’s exact test or the Chi-square test, as
appropriate; continuous data were compared using the Mann Whitney-U
test. Spearman’s rank coefficient was used to assess correlation between
continuous variables. Comparisons of survival were made using Cox
proportional hazards models within the Survival package, presented as
hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs).
Median follow-up time was calculated using the reverse Kaplan–Meier
method. Correction for multiplicity of testing was applied using the
Bonferroni method where specified.
The impact of outlier cases on the final integrated classification
taxonomy was assessed using a leave-one-out jackknife approach; survival
analysis was repeated for all possible iterations of a single missing sample.
The outcome of the jackknifing analysis is presented as the median HR of
all iterations, alongside the HR variance (σ2). Applicability of the final
integrated classification taxonomy to non-identical EnOC cohorts was
assessed by the generation of 1000 simulated cohorts via resampling with
replacement (1000 iterations of N= 90 resampling) and analysis of the HR
distribution across these simulated datasets; results are reported as the
median HR, HR variance and the proportion of iterations demonstrating a
large effect size (HR < 0.30).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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